Donation/Investment
Donations
At Stratis Bio our goal is to not only be able to provide relief to many of these CRPS patients but also continue research to develop the strategies which brings the disease to full remission.Your donation will allow us to continue our work towards healing the disease as well as providing relief to many who do not have funds for medical treatment. Eventually we will have a sister non-profit to continue assisting CRPS patients as well as others who are impacted by our other products in development (for example reintegration of addicts taking our addiction relief formulation). Donations are not tax deductible at this time.
CRPS is one of the most difficult diseases to treat, the etiology of which is not truly defined. It is also rare with around 200,000 new cases a year and thus has not received a great amount of research/pharma attention. Further it is the most painful disease known to man on the McGill scale, being likened to an amputation without anesthesia , and the pain never ends. Because the prognosis is a life with intractable pain it is estimated that over 70% of CRPS sufferers seriously contemplate suicide with 5-15% attempting suicide. This translates to 7 individuals attempting suicide every day in the US. Compounding the difficulty of the disease the diagnosis rate is only about 50% leaving sufferers in a continuous medical loop of doctors trying to understand the disease. Lastly, although the majority are left truly incapacitated, it is very difficult to obtain any form of social security/disability. This has left many destitute and not able to afford medical care which can run into the 10’s of thousands annually.
Investments
Chronic pain is an epidemic in developed countries with the US market value estimated at $30 Billion and $80 Billion for the global market. It is expected to grow at 5-6% annually. There are no products currently available which can be taken orally and can replace opioids with the efficacy of our own. Further, there are an estimated 1.2 million CRPS sufferers in the US with around 30-50% of cases not finding pain relief greater than 50%. This product gives greater than 50% relief in over 60% of sufferers who have tried it and significant relief to sufferers receiving partial relief from other treatments. Based on these numbers the estimated CRPS market in the US is $300 Million to $500 Million. The efficacy of our product suggests that we should easily capture 20% of the US market although we are attempting to address the CRPS community with as little cost as possible.
We are allowing investments with a goal of raising minimally $80,000. The vehicle is designed for conversion to a percentage of the value of the company at the time of conversion. The return on investment is capped at a 25 fold return.
The minimum investment is $500 and the maximum is $4,000. Each $500 gives the right to convert for 0.125% of the value of the company at the time of conversion.
As an example with a $4,000 investment
-
This gives the right to convert for 1% of the company value.
-
Company valued at $10 Million or an estimated 0.03% of the chronic pain market at the time of conversion would give a $100,000 return
-
For CRPS in general capturing 10% of the US market would give an estimated company valuation of $50 Million.
We believe that the nature of this product in the pain market will lead to a rapid growth with the company reaching a $50 Million valuation in less than 5 years. This does not include additional value from the opioid dependency product in development which should be on the market by Q2 2025.
Further, this is the first of a number of products in the pipeline, for example, the addiction formulation which is showing promise with opioid addiction as well as tobacco addiction.
